|分野（sector）||Capital Goods 資本財（工業製品）|
|産業（industry）||Biotechnology: Laboratory Analytical Instruments|
Bionano Genomics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2021/11/02 20:30:00 Intrado Digital Media
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that, in accordance with Nasdaq Listing Rule 5635(c)(4), the Compensation Committee of its Board of Directors granted the following non-qualified stock options pursuant to the companys 2020 Inducement Plan to new employees as an inducement material to such employees entering into employment with Bionano:
Vanguard Group Inc. Grows Stock Position in Bionano Genomics, Inc. (NASDAQ:BNGO) 2021/11/01 09:38:45 Transcript Daily
Vanguard Group Inc. raised its stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) by 59.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 14,855,436 shares of the companys stock after acquiring an additional 5,559,597 shares during the period. Vanguard Group Inc. owned about 0.05% of Bionano Genomics worth $108,890,000 as of its most 
Bionano Genomics to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 4, 2021 2021/10/28 20:30:00 Intrado Digital Media
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the third quarter ended September 30, 2021 and to highlight recent corporate progress.
Bionano Genomics Is Still Set to Pay Off Big for Patient Investors 2021/10/28 18:26:05 InvestorPlace
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It may take time for it to potentially move back to its all-time high of $15.69 per share. But given that''s nearly triple what it trades today, patience could pay off big with BNGO stock. The post Bionano Genomics Is Still Set to Pay Off Big for Patient Investors appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom Americas #1 EV Stock Still Flying Under the Radar
The Buzz Show: Bionano Genomics, Inc. (NASDAQ: BNGO) Joins US Small-Cap Russell 2000® Index 2021/06/28 21:55:27 Financial Buzz
FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Bionano Genomics, Inc. up 6% after Becoming a Member of US Small-Cap Russell 2000® Index Bionano Genomics, Inc. (NASDAQ: BNGO) gained over 6% in premarket trading after the Company said it was added as a member of the US small-cap Russell 2000® Index, effective The post The Buzz Show: Bionano Genomics, Inc. (NASDAQ: BNGO) Joins US Small-Cap Russell 2000® Index first appeared on Financial Buzz .
Bionano Genomics (BNGO.Q), a Small Cap Biotechnology Company with Big Potential 2021/06/28 16:08:08 Equity Guru
Bionano Genomics (BNGO.Q), a genome analysis company providing tools and services to scientists and clinicians, announced today that it has been added as a member of the US small-cap Russell 2000® Index. We are pleased Bionano has been added to the Russell indexes, which means Bionanos share performance is now included in a leading benchmark  The post Bionano Genomics (BNGO.Q), a Small Cap Biotechnology Company with Big Potential appeared first on Equity.Guru .
Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday 2021/05/14 14:27:47 Benzinga
Bionano Genomics, Inc. (NASDAQ: Full story available on Benzinga.com
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates 2021/05/13 22:15:10 Yahoo Finance
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 0.00% and 13.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Does Bionano Genomics Deserve a Place in Your Portfolio? 2021/04/29 22:30:45 Investing.com
Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today 2021/04/27 16:03:22 Benzinga
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ), Sol-Gel Technologies Ltd. (NASDAQ: SLGL ), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ), DermTech, Inc. (NASDAQ: DMTK ) and Bionano Genomics, Inc. (NASDAQ: BNGO ) are among the biggest health care movers Tuesday. Cyclerion Slips On Study Delay: Cyclerion, a clinical-stage biopharma developing treatments for restoring cognitive functions, provided a clinical pipeline update. The company delved on the development strategy and execution for its lead asset CY6463, which is being evaluated in Alzheimer's disease with vascular pathology as well as mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes, or MELAS. The MELAS study is enrolling more slowly than initially projected, primarily due to COVID-19, the company said. It now expects to report data from the Phase 2a pilot study by year-end 2021. Cyclerion shares were slipping 16.39% to $2.60. Sol-Gel Down On Potential Delay In FDA Decision: Sol-Gel's new drug application for Epsolay in the …
関連キーワード （― 米国株 BNGOW Bionano Genomics Inc.）